BUPROPION AS A MODULATOR OF DRUG ACTIVITY
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1 . A method of treating treatment resistant depression, comprising orally co-administering: a daily dose of bupropion that is about 150 mg to about 250 mg and a daily dose of dextromethorphan that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion is bupropion hydrochloride, or the free base form or another salt form of bupropion and the dextromethorphan is dextromethorphan hydrobromide, or the free base form or another salt form of dextromethorphan; wherein the bupropion and the dextromethorphan are the only therapeutically active compounds to be co-administered; wherein the dextromethorphan is formulated for immediate release and the bupropion is formulated for sustained release; and wherein orally co-administering the bupropion and the dextromethorphan results in the human being experiencing a therapeutic effect.
2 . The method of claim 1 , wherein after orally co-administering the bupropion and the dextromethorphan, the human being experiences an improvement in a depressive symptom as compared to baseline.
3 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective in treating treatment resistant depression than orally administering a placebo.
4 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective in treating treatment resistant depression than orally administering the same amount of the dextromethorphan alone.
5 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered once daily.
6 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered twice daily.
7 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered for at least 14 consecutive days.
8 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered for at least 30 consecutive days.
9 . The method of claim 1 , wherein the weight ratio of the daily dose of the dextromethorphan to the daily dose of the bupropion is about 0.3 to about 0.5.
10 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered once a day for 1 day and are co-administered twice a day thereafter.
11 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered once a day for 2 days and are co-administered twice a day thereafter.
12 . The method of claim 1 , wherein the bupropion and the dextromethorphan are orally co-administered once a day for 3 days and are co-administered twice a day thereafter.
13 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing anxiety.
14 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in improving concentration, reducing mental slowing, or a combination thereof.
15 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in improving mood, reducing feelings of intense sadness, reducing despair, reducing pessimistic worry, or a combination thereof.
16 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing agitation, irritability, restlessness, or a combination thereof.
17 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing guilt, feelings of worthlessness, self-deprecation, or a combination thereof.
18 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing anger, reckless behavior, suicidal thoughts or attempts, or a combination thereof.
19 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing insomnia.
20 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing anorexia, appetite loss, weight loss, or a combination thereof.
21 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing weight gain.
22 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing decreased energy, fatigue, decreased libido, or a combination thereof.
23 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing aches, pains, headaches, cramps, or a combination thereof.
24 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing digestive issues.
25 . The method of claim 1 , wherein orally co-administering the bupropion and the dextromethorphan is more effective than orally administering a placebo in reducing abnormal hormonal circadian rhythms.